C4 Therapeutics (CCCC) Well Positioned With Cemsidomide Trial Data

C4 Therapeutics Inc. (NASDAQ:CCCC) is one of the 11 most popular AI penny stocks to buy now. On February 23, Brookline ...

C4 Therapeutics: Cemsidomide Progress Keeps The Long-Term Thesis Intact

C4 Therapeutics delivered strong 4Q25 results, with revenue up 111.5% YoY and operating expenses tightly controlled. Click for my latest analysis of CCCC stock.
Mena FN

C4 Therapeutics Announces First Patient Dosed In Phase 2 MOMENTUM Trial Of Cemsidomide, An Oral IKZF1/3 Degrader, In Combination With Dexamethasone For Relapsed/Refractory ...

(MENAFN- GlobeNewsWire - Nasdaq) Enrollment for Phase 2 MOMENTUM Trial Expected to Be Completed in Q1 2027 Phase 1b Trial of Cemsidomide in Combination with Elranatamab on Track to Initiate in Q2 2026 ...
Investing

C4 Therapeutics doses first patient in phase 2 myeloma trial

"Initiating the Phase 2 MOMENTUM trial, which builds upon the compelling anti-myeloma activity and differentiated safety profile established in the Phase 1 trial, is a critical step for cemsidomide to ...
Seeking Alpha

C4 Therapeutics to Present Data from the Ongoing Phase 1/2 Trial of Cemsidomide in Multiple Myeloma and Non-Hodgkin’s Lymphoma at the American Society of Hematology (ASH ...

WATERTOWN, Mass., Nov. 05, 2024 (GLOBE NEWSWIRE) -- C4 Therapeutics, Inc. (CCCC), a clinical-stage biopharmaceutical company dedicated to advancing targeted protein degradation science, today ...

C4 Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Recent Business Highlights

Cemsidomide Advancing into Later-stage Development with Potential for Accelerated Approval; First Patient Dosed in the Phase 2 MOMENTUM Trial for ...